A new funding initiative to support the use of existing HIRN datasets and resources to explore unique and innovative hypotheses designed to accelerate breakthroughs and advances in type 1 diabetes (T1D) research.
Key Dates:
|
Posted Date: |
April 1, 2025 |
Learn more at: https://hirnetwork.org/datascholars2025
Please refer to the RFP for details: HIRN RFP Data Scholars Initiative (2392 downloads )
The Leona M. and Harry B. Helmsley Charitable Trust’s (Helmsley) Type 1 Diabetes (T1D) Program aims to support the discovery and development of new therapies to prevent or delay T1D and the identification and validation of biomarkers to predict disease initiation and progression.
T1D is a complex autoimmune disease where insulin-producing beta cells in the pancreas are targeted by immune cells. The predisposing factors, triggers, and other elements that affect disease pathogenesis in humans are not yet fully identified. Understanding these drivers of disease could lead to discoveries of new drug targets, guide intervention strategies to halt the disease, or improve prediction of disease development.
To date most T1D preclinical and clinical research has focused on the role T cells play in disease pathogenesis. However, innate immune cells are the first and most abundant type of immune cells in the pancreas, especially in individuals with T1D. Moreover, data, mostly generated from animal experiments, suggests that these cells might play different roles in T1D: from activating T cells and/or recruiting them to the pancreatic islets, to promoting inflammation or inducing immune tolerance. However, what leads to an increase in innate immune cells in the pancreas during T1D, its significance, and what role these cells play in disease in humans is not yet fully understood.
Learn More HERE
Posted: March 3, 2025
Concept notes due: April 30, 2025
Full grant proposal due: July 30, 2025
Start date: February 2026
The New Investigator Gateway Award in T1D Research is designed to support a robust pipeline of innovative projects and talented new investigators in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new Program Directors/Principal Investigators (PD/PIs) to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New and Early Stage Investigators to increase their understanding of key questions in the field, to network, and to establish unique and potentially long-lasting collaborations that will propel their careers forward. Bringing New and Early Stage Investigators into existing collaborative research networks will also benefit the networks by providing new ideas and perspectives.
This NOFO is associated with the Special Diabetes Program which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.
Application due dates:
Follow
